Cefdinir Powder, For Suspension
NDC Package 68788-4106-1
Package Information
Cefdinir powders is to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension and other antibacterial drugs, cefdinir for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a powder, for suspension delivery system. Marketed by Preferred Pharmaceuticals Inc., this product is identified by NDC 68788-4106 and is authorized under FDA application ANDA065259.
Identification & Billing
- RxCUI: 476576 - cefdinir 250 MG in 5 mL Oral Suspension
- RxCUI: 476576 - cefdinir 50 MG/ML Oral Suspension
- RxCUI: 476576 - cefdinir 250 MG per 5 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68788 - Preferred Pharmaceuticals Inc.
- 68788-4106 - Cefdinir
- 68788-4106-1 - 100 mL in 1 BOTTLE
- 68788-4106 - Cefdinir
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68788-4106-1 identifies a specific commercial package of 100 ml in 1 bottle of Cefdinir, a human prescription drug labeled by Preferred Pharmaceuticals Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 100 billable units per package. This powder, for suspension is formulated for oral use and contains cefdinir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Preferred Pharmaceuticals Inc. on April 21, 2026. The current certification is valid through December 31, 2027.
How is this Preferred Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68788410601. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.